Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Crossword Cybersecurity Plc LSE:CCS London Ordinary Share GB00BNG2LT65 ORD 0.5P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 39.50 0.00 08:00:00
Bid Price Offer Price High Price Low Price Open Price
38.00 41.00 39.50 39.50 39.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Software & Computer Services 1.63 -2.28 -0.46 23
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 39.50 GBX

Crossword Cybersecurity (CCS) Latest News

More Crossword Cybersecurity News
Crossword Cybersecurity Investors    Crossword Cybersecurity Takeover Rumours

Crossword Cybersecurity (CCS) Discussions and Chat

Crossword Cybersecurity Forums and Chat

Date Time Title Posts
15/6/202119:46Crossword Cybersecurity PLC - Best Cyber Security company on the market!79
10/11/202011:15Crossword Cybersecurity28
18/10/201110:33Overlooked, but steadly making excellent progress200
09/3/201009:14Clarity Commerce Solutions Plc31
21/10/200105:36Clarity interim results2

Add a New Thread

Crossword Cybersecurity (CCS) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Crossword Cybersecurity trades in real-time

Crossword Cybersecurity (CCS) Top Chat Posts

DateSubject
23/7/2021
09:20
Crossword Cybersecurity Daily Update: Crossword Cybersecurity Plc is listed in the Software & Computer Services sector of the London Stock Exchange with ticker CCS. The last closing price for Crossword Cybersecurity was 39.50p.
Crossword Cybersecurity Plc has a 4 week average price of 39p and a 12 week average price of 39p.
The 1 year high share price is 470p while the 1 year low share price is currently 39p.
There are currently 58,042,630 shares in issue and the average daily traded volume is 19,418 shares. The market capitalisation of Crossword Cybersecurity Plc is £22,926,838.85.
04/6/2021
07:00
kaos3: as I love sudoku, crosswords, enigma ... you got my juice flowing the wiseone number of posts ever, writing style, semantics, age, share... regards from a slovenian gardener
04/6/2021
06:45
thewiseone2019: Hi, sorry only just seen your reply! Was older when I saw EFC for 1st time live, 1974, 3-2 win over Leeds, super game! Should have won the League, too many draws at home, 9. The charts are showing a different price for last 6 months, it did show £4.40 early May, I feel I've been duped! 46.2p bought on Tues! High point 50p this year, not impressed! Eyebrows has gone, hypocrital as well.Madrid doubled his salary, so was Bs what he told Mishiri! Question is who next? Conte? Fonseca? Either for me!
27/5/2021
20:22
thewiseone2019: Hi Toffeeman, off topic slightly, are you an Everton fan like myself? (sadly atm) This share ought to be jumped on now, with such powerful board members im sure there will be a bounce back!
26/5/2021
08:40
toffeeman: Bit of a shock this morning! - didn't read about the share split! Anyone attending web-cast?
04/5/2021
15:56
bandflex: I think it is just a recognition that vaccine certificates will be the next big thing in the market and CCS are likely to benefit. Crossword working with Verifiable Credentials Ltd on its Innovate UK funded project to allow NHS laboratories to issue Covid-19 immunity certificates. Share cap is still small and the up coming 10 for 1 share split should make the shares more liquid and attractive to retail investors.
08/3/2021
18:00
outlawinvestor: CCS is presenting at Proactive One2One Investor Forum on 25 March. https://www.proactiveinvestors.co.uk/register/event_details/327
05/3/2021
11:29
a_game: Looks like CCS has bottomed out and turned the corner - long overdue, this is a fast growing company in a super hot sector lead by top tier management. Been holding since IPO, confident we'll see a great rise here in the months ahead.
18/2/2021
09:55
a_game: Crossword working with Verifiable Credentials Ltd on its Innovate UK funded project to allow NHS laboratories to issue Covid-19 immunity certificates. ---- It's becoming increasingly clear that vaccine/immunity certificates will be required for many things, in particular, international travel. The work with NHS on this could be a game changer for CCS.
28/12/2020
14:42
outlawinvestor: Los Angeles Vaccine Recipients Can Put the Proof in Apple Wallet https://www.bloomberg.com/news/articles/2020-12-28/los-angeles-vaccine-recipients-can-put-the-proof-in-apple-wallet?srnd=premium-europe This is more or less what CCS is collaborating on as per 10-Nov RNS. Apparently, global big players like IBM are in the race to implement vaccine record solutions mindful of ethical and privacy concerns.
13/4/2019
07:02
timbo003: I have a few of these having purchased shares in the last two placings (March 2018 whilst still on NEX and in December 2018 at the AIM IPO). I attended the AGM last May and wrote up a few notes which I posted on the ShareSoc meetings blog as there was zero interest on ADVFN at the time (see report below) My shares came with EIS tax reliefs, so I will be hanging around for at least the next 2-3 years ######################################################### Crossword Cybersecurity Plc (NEX: CCS) 2018 AGM This year’s Crossword Cybersecurity Plc (CCS) AGM was held at the offices of Shakespeare Martineau LLP, 6th Floor, 60 Gracechurch Street, London EC3V on Wednesday 30th May 2018 commencing at 3.00pm. For investors who are unfamiliar with the company, CCS is a technology commercialisation company focusing exclusively on the cyber security sector, with the technology sourced through collaborations with Universities. CCS was founded in March 2014 by the current CEO, Tom Ilube and then subsequently floated on the now defunct Danish GXG exchange in September 2014 at 145p/share which valued CCS at around £2.1m. The company transferred to the NEX exchange (then known as ISDX) in September 2015 (following the demise of the GXG earlier in the year). There was no fund raise to accompany the NEX IPO which is somewhat unusual, but the last fund raise on the GXG exchange had been at 190p/share in June 2015, valuing the company at around £4.5m. The most recent funding round was in March 2018 raising £2m in an oversubscribed placing and subscription at 270p/share and this corresponded to a post money valuation of approximately £10.8m. The shares are currently quoted at 330 – 400p. Links to the company web site, the latest Annual Report and other useful information are given below: * Web site: https://www.crosswordcybersecurity.com/ * Annual report, financial year ending Dec 2017: https://goo.gl/GSoKPe * Admission Document: https://goo.gl/vz15fy * Recent Interview with Tom Ilube (CEO): https://youtu.be/AIzXOrUKv6c * Recent Interview with Sir Richard Dearlove (Chairman): https://youtu.be/DrCRkyl7CZg# * Recent interview with Prof. David Stupples (NED): https://youtu.be/pEkHQ7Jv38s There were around 25 attendees at the meeting, which included a number of employee shareholders, the BOD and the usual AGM functionaries. I was the only retail shareholder present and as a result, I ended up asking most of the questions. The Chairman, Sir Richard Dearlove, kicked off the meeting with the formal business. I just had one question for this part of the meeting which concerned resolutions 7 and 8 (allotment of shares and disapplication of pre-emption rights) where I asked what was the maximum number of shares (expressed as a percentage of the existing share capital) that could be issued if these resolutions were approved? The answer was 22%. When it came to the voting, all 8 resolutions were passed unanimously with a show of hands. On the proxy votes, resolutions 1-6 (approval of the accounts, re-election of 4 directors and reappointment of auditors) received 100% in favour and resolution 7 and 8 received 84% in favour (16% against). The CEO then gave a 30 minute presentation which included a brief synopsis of the previous financial year (ending Dec 2017) during which time the BOD was strengthened and a new sales force established. The headcount now includes 10 staff deployed in sales (based in the UK) and 8 in R&D (based in Poland). Group revenues doubled to £737K and 2018 has got off to a very strong start with most of the new revenue coming from Rizikon Assurance (a new B2B cybersecurity solution for medium to large enterprises) which is expected to be the main engine of growth over the next couple of years. The presentation also included a brief outline of the company’s strategy which is to select the most promising cybersecurity technology solutions emanating from collaborating Universities and to monetize these technologies either through in-house development and subsequent product launch, or through JVs with the Universities. The company has collaborative agreements with 10 different Universities (8 UK, 1 Swiss, 1 USA) but there are no immediate plans to add more. The main target market for resulting Cybersecurity products is medium to large Commercial Enterprises and CCS has just launched Rizikon, which is their first product arising from one of the University Collaborations. Rizikon enables a client company to monitor the cybersecurity risks and other risks such as GDPR compliance arising from their supplier base. The product is currently sold in two formats: Rizikon Standard (for SMEs) and Rizikon Assurance (for medium to large enterprises) and it is currently the only commercial software solution available which specifically addresses these particular problems. Rizikon is supplied on a SaaS basis with a subscription charge of up to up to £30/supplier/annum for large businesses. There are an estimated 10,000 UK businesses with revenues of £25m or more and these businesses could each have between 1,000 and 5,000 suppliers, so the addressable UK market is conservatively estimated at around £300m. If Rizikon Assurance were to capture just 5% of the UK market, it could translate to revenues of circa £15m /year; furthermore, Rizikon should be suitable for roll out to many other major geographical markets, subject to making appropriate changes for each local market. The company is also actively looking at the possibility of signing on with a large partner to assist in distributing the product and this should lead to additional sales. During the year CCS launched a major new initiative, CyberAI, which is looking at applying Artificial Intelligence to real world Cybersecurity problems. Three Universities and several large Financial Services firms are closely involved with the project and it is anticipated that the output from CyberAI will help feed the product pipeline for the next few years. The initial output comprised of a short list of initiatives which were subsequently whittled down to just one, this will be tested for Proof of Concept later this year and then hopefully undergo further development next year with the objective of ending up with a new innovative cybersecurity software product for SaaS commercialisation. Following the presentation there was a Q&A session which lasted for 20 – 30 minutes before the meeting closed (see Q&A summary details below). After the meeting most of the attendees stayed around for coffee and biscuits and this gave me a chance to talk to some of the Senior management including the CFO and COO. I also spoke with Professor David Stupples (NED), who was responsible for the work leading up to the development of Rizikon and also the Sir Richard Dearlove (Chairman), who was the Head of MI6 from 1999 – 2004. Q&As Q: CCS appears to be a hybrid between a software developer deriving revenues from SaaS and an Investment company which owns equity stakes in university spinouts. As a general rule, the market tends to rate the former a lot higher than the latter, Is this reflected in your priorities? A: Yes, we prefer to licence technology and develop it ourselves rather than take equity stakes in University spinouts, however, sometimes a University may insist on the latter. We aspire to have perhaps 6 Rizicon type products either launched, or in development in the next 3 – 4 years. Q: You talked about taking on a large partner to assist Rizicon sales and eventually other SaaS products. What sort of companies are these large partners and can you expand on how such a partnership might work? A: The partner could be an IT services company, or maybe one of the big four accountancy firms. One such potential partner we have spoken to is a US based IT Service Company, employing 200K staff worldwide and with a turnover of around $15Bn. Any large partner would probably want to see revenue potential of £30m – £40m before signing up. The industry norm would be to split revenues, with up to 75% going to the software developer (CCS in this case), but there would be no upfront fee payable on initiation of a partnership deal. Q: Who are the nearest competitors and what barriers to entry are there for a new entrant in the future? A: Rizikon is the only purpose built software in this space, the technology came from City University London and the algorithms were inspired by software used in the nuclear safety industry. The work performed to develop the software has not been published; therefore it would not be easy to reproduce. Parts of the SAP Ariba software solution are probably the closest thing there is to a competitor. Q: Who do you target during the sales process for Rizikon? A: Typically we talk to the Heads of Procurement, but on occasions it may be the Head of Security or Head of Quality Assurance. Q: You talked briefly about a possible AIM IPO, this sounds like an excellent idea as it would assist liquidity as CCS shares are rarely traded on NEX and many popular online brokers will not deal in NEX shares, so what are the chances that an IPO will go ahead? A: We are actively exploring the possibility for an AIM IPO for later this year. The likelihood of this occurring will depend on market conditions, which could be influenced by macro factors such as the outcome of Brexit negotiations. Summary When I acquired my CCS shares in the March 2018 placing, I knew very little about the company and there was very little time for due diligence after I was made aware of the placing opportunity, however, I do firmly believe that demand for effective cybersecurity is only ever likely to increase, as cyber criminals develop ever more innovative and sophisticated techniques to carry out their illegal activities. Furthermore, the placing shares were offered at an attractive 30% discount and they came with EIS tax reliefs, so despite my lack of background knowledge on the company, I took the decision to invest. Unfortunately (for me) the scale back on the placing shares was around 60% (presumably due to demand) so I ended up with somewhat less shares than I originally requested. This AGM was the first opportunity I had to meet the management and to learn more about the business. The company is still at an early stage of development, it is loss making and the revenues are still small (albeit growing rapidly). However, the Management and Directors do appear very capable and the plans to grow the business seem realistic. I was pleased to learn about the intended AIM IPO later this year and assuming the switch to Aim is accompanied by another attractively priced (EIS qualifying) share placing, I will almost certainly apply for more shares in the IPO should the opportunity arise. #########################################################
Crossword Cybersecurity share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
CCS
Crossword ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210723 18:03:46